GlassScriptPhysician profile
Resmi Premji
NPI 1215208913
$2,573.04
in general payments reported to CMS, 2019-2025
20 companies · $328 in 2025
The $328 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $506 · 2020: $83.10 · 2021: $55.60 · 2022: $231 · 2023: $825 · 2024: $545 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,683 · Education: $14.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,683.03 |
| Education | $14.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $613.96 | 2020-2025 | Freestyle Libre 3 |
| Insulet Corporation | $335.16 | 2019-2025 | Omnipod |
| Corcept Therapeutics | $334.44 | 2024-2025 | Korlym |
| Beta Bionics, INC. | $253.53 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amgen INC. | $169.12 | 2021-2024 | Evenity, Prolia, Tepezza |
| Tandem Diabetes Care, INC. | $131.17 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals LP | $116.37 | 2019 | |
| Alexion Pharmaceuticals, INC. | $100.81 | 2024 | Strensiq |
| Mannkind Corporation | $98.59 | 2019-2020 | |
| Lilly USA, LLC | $90.92 | 2019-2024 | Mounjaro, Zepbound |
| Dexcom, INC. | $62.23 | 2023-2025 | Dexcom G6 Transmitter |
| Medtronic Minimed, INC. | $52.29 | 2019-2020 | |
| Novo Nordisk INC | $42.64 | 2019-2022 | |
| Medtronic, INC. | $33.07 | 2021-2023 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $30.93 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bigfoot Biomedical INC | $30.29 | 2022 | |
| Ascendis Pharma Endocrinology INC | $23.74 | 2025 | Yorvipath |
| Bayer Healthcare Pharmaceuticals INC. | $21.57 | 2023 | |
| Merck Sharp & Dohme LLC | $17.69 | 2019 | |
| Radius Health, INC. | $14.52 | 2024 | Tymlos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Resmi Premji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.